Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 30 May, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Mangalam Drugs and Organics Ltd

About the Company - Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd. is a Public Limited Listed company incorporated on 18/04/1972 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1972PLC116413 and registration number is 116413. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 451.07 Cr. and Equity Capital is Rs. 15.83 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsRupam Building, 3rd Floor, 239, P.D. Mello Road, Mumbai Maharashtra 400001investor@mangalamdrugs.com
http://www.mangalamdrugs.com
Management
NamePosition Held
Mr. Govardhan M DhootChairman & Managing Director
Mr. Brijmohan M DhootWhole Time Director
Mr. Rakesh K MilwaniNon Exe.Non Ind.Director
Mr. Rukmesh P DhandhaniaIndependent Director
Mrs. Nidhi S MundadaIndependent Director
Mr. Praveen SaxenaIndependent Director

Basic Stock Data of Mangalam Drugs and Organics Ltd

Last Updated: May 30, 2024, 6:19 am

Market Cap 170 Cr.
Current Price 107
High / Low132/85.2
Stock P/E
Book Value 89.9
Dividend Yield0.00 %
ROCE1.19 %
ROE6.15 %
Face Value 10.0
PEG Ratio0.00

Competitors of Mangalam Drugs and Organics Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Lyka Labs Ltd 364 Cr. 110144/92.4 20.60.00 %3.78 %6.32 % 10.0
Themis Medicare Ltd 1,916 Cr. 208266/13144.0 41.00.24 %13.9 %12.1 % 1.00
Kilitch Drugs (India) Ltd 542 Cr. 337470/17543.6 1040.00 %9.88 %5.40 % 10.0
Kopran Ltd 1,137 Cr. 236292/14122.3 1021.27 %13.8 %11.0 % 10.0
Jubilant Pharmova Ltd 11,255 Cr. 706741/318308 3400.71 %3.13 %6.89 % 1.00
Industry Average3,042.80 Cr319.4083.58121.520.44%8.90%8.34%6.40

Mangalam Drugs and Organics Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales88.6992.90104.78123.02101.88120.96109.49108.3363.3291.1187.4681.5697.34
Expenses76.0981.3294.43109.2687.56110.7799.1299.8956.8490.8790.9479.3790.36
Operating Profit12.6011.5810.3513.7614.3210.1910.378.446.480.24-3.482.196.98
OPM %14.21%12.47%9.88%11.19%14.06%8.42%9.47%7.79%10.23%0.26%-3.98%2.69%7.17%
Other Income1.270.000.520.000.000.000.010.000.130.290.020.030.00
Interest2.352.222.962.982.692.533.542.563.223.433.413.243.31
Depreciation2.332.522.392.502.672.692.602.762.882.753.423.733.62
Profit before tax9.196.845.528.288.964.974.243.120.51-5.65-10.29-4.750.05
Tax %30.03%68.57%19.93%45.41%55.02%-34.61%29.01%28.85%15.69%22.30%7.29%25.05%-920.00%
Net Profit6.432.154.424.534.026.693.002.230.43-4.39-9.54-3.560.50
EPS in Rs4.061.362.792.862.544.231.901.410.27-2.77-6.03-2.250.32

Last Updated: May 7, 2024, 11:54 pm

Mangalam Drugs and Organics Ltd Quarterly Chart

Mangalam Drugs and Organics Ltd Profit & Loss

Last Updated: May 2, 2024, 6:33 am

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales153124123221295299269228282380451372323
Expenses139129113200257252222218259327402347318
Operating Profit14-4102038474710245349265
OPM %9%-4%8%9%13%16%17%4%8%14%11%7%2%
Other Income12000-01015000
Interest10101010910129109111313
Depreciation4444457789101113
Profit before tax1-17-46243129-6640282-20
Tax %44%30%22%-2%33%29%32%-40%-32%29%29%43%
Net Profit1-12-36162220-8828201-17
EPS in Rs0.48-8.95-2.314.6611.1514.0812.57-5.075.2117.6712.420.80-10.78
Dividend Payout %0%0%0%0%0%0%4%0%0%0%0%0%

Mangalam Drugs and Organics Ltd Profit & Loss Yearly Chart

Mangalam Drugs and Organics Ltd Growth

Compounded Sales Growth
10 Years:12%
5 Years:7%
3 Years:10%
TTM:-11%
Compounded Profit Growth
10 Years:8%
5 Years:-42%
3 Years:-46%
TTM:-238%
Stock Price CAGR
10 Years:36%
5 Years:15%
3 Years:-10%
1 Year:-11%
Return on Equity
10 Years:13%
5 Years:8%
3 Years:12%
Last Year:1%

Last Updated: May 1, 2024, 10:33 am

Mangalam Drugs and Organics Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital13131313141616161616161616
Reserves251310163970888088115135136123
Borrowings61737778606669655270888989
Other Liabilities2316256347385450756490119159
Total Liabilities122115125170160190227211231264328360387
Fixed Assets575553535493102103101118135142151
CWIP0000500016690
Investments0000020000000
Other Assets65597211710095125107128140188208236
Total Assets122115125170160190227211231264328360387

Mangalam Drugs and Organics Ltd Reserves and Borrowings Chart

Mangalam Drugs and Organics Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 7-17142243252231282640
Cash from Investing Activity -6-2-2-4-11-39-16-9-7-31-27-22
Cash from Financing Activity -02-5-10-11-3-9-11-2333-17
Net Cash Flow0-101-00-010-111

Mangalam Drugs and Organics Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days217088733745612852523846
Inventory Days165112170134856913217512185139200
Days Payable433997128373882771066365141
Cash Conversion Cycle1431441617985751111266774112104
Working Capital Days961251227976709910266758493
ROCE %12%-7%6%16%30%32%25%2%11%27%18%6%

Mangalam Drugs and Organics Ltd Financial Efficiency Indicators Chart

Mangalam Drugs and Organics Ltd Share Holding Pattern

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
Promoters50.53%50.53%50.53%50.53%50.42%50.41%50.31%50.31%50.31%50.31%50.31%50.31%
FIIs0.00%0.00%0.00%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.26%
DIIs0.01%0.01%0.01%0.01%0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public49.46%49.46%49.46%49.36%49.47%49.49%49.58%49.59%49.58%49.59%49.59%49.42%
No. of Shareholders21,82721,07120,66820,08418,98818,48317,91117,94317,89017,97818,61019,173

Mangalam Drugs and Organics Ltd Shareholding Pattern Chart

No. of Mangalam Drugs and Organics Ltd Shareholders

This stock is not held by any mutual fund

Mangalam Drugs and Organics Ltd ROCE Trend

Mangalam Drugs and Organics Ltd EPS Trend

Mangalam Drugs and Organics Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)0.8012.4217.675.21-5.07
Diluted EPS (Rs.)0.8012.4217.675.21-5.07
Cash EPS (Rs.)7.7418.8923.4710.40-0.59
Book Value[Excl.RevalReserv]/Share (Rs.)96.0095.1282.7465.6760.44
Book Value[Incl.RevalReserv]/Share (Rs.)96.0095.1282.7465.6760.44
Revenue From Operations / Share (Rs.)235.18284.98240.17178.39143.78
PBDIT / Share (Rs.)16.4031.0536.6615.726.32
PBIT / Share (Rs.)9.4524.5730.8610.521.84
PBT / Share (Rs.)1.4017.5224.973.95-3.62
Net Profit / Share (Rs.)0.8012.4217.675.21-5.07
PBDIT Margin (%)6.9710.8915.268.804.39
PBIT Margin (%)4.028.6212.845.891.27
PBT Margin (%)0.596.1410.392.21-2.52
Net Profit Margin (%)0.344.357.352.92-3.52
Return on Networth / Equity (%)0.8313.0521.357.93-8.39
Return on Capital Employeed (%)7.7019.6131.4713.742.41
Return On Assets (%)0.355.9810.643.57-3.79
Long Term Debt / Equity (X)0.120.160.050.040.08
Total Debt / Equity (X)0.440.470.440.440.61
Asset Turnover Ratio (%)1.081.531.541.281.04
Current Ratio (X)1.251.401.231.091.16
Quick Ratio (X)0.410.500.680.490.34
Inventory Turnover Ratio (X)2.183.864.152.582.53
Interest Coverage Ratio (X)2.044.406.222.391.16
Interest Coverage Ratio (Post Tax) (X)1.102.764.001.790.07
Enterprise Value (Cr.)220.52233.04214.8092.44144.97
EV / Net Operating Revenue (X)0.590.510.560.320.63
EV / EBITDA (X)8.504.743.703.7214.50
MarketCap / Net Operating Revenue (X)0.410.360.410.170.38
Price / BV (X)1.021.081.200.460.91
Price / Net Operating Revenue (X)0.410.360.410.170.38
EarningsYield0.010.120.170.17-0.09

Mangalam Drugs and Organics Ltd Profitability Ratios (%)

Mangalam Drugs and Organics Ltd Liquidity Ratios

Mangalam Drugs and Organics Ltd Liquidity Ratios (%)

Mangalam Drugs and Organics Ltd Interest Coverage Ratios (%)

Mangalam Drugs and Organics Ltd Valuation Ratios

Fair Value

Fair Value: ₹84.59

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Overvalued: 20.94% compared to the current price ₹107

Default values used*: Deafault value of 15 for Stock P/E is used

Intrinsic Value: ₹48.01

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Overvalued: 55.14% compared to the current price ₹107

Default values used*: Deafault value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -43.25%

*Investments are subject to market risks

Strength and Weakness of Mangalam Drugs and Organics Ltd Stock

StrengthWeakness
  1. The company has higher reserves (72.15 cr) compared to borrowings (72.08 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (270.77 cr) and profit (9.23 cr) over the years.
  1. The stock has a low average ROCE of 14.83%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 90.58, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 106.75, which may not be favorable.

FAQ

What is the latest fair value of Mangalam Drugs and Organics Ltd?

The latest fair value of Mangalam Drugs and Organics Ltd is ₹84.59.

What is the Market Cap of Mangalam Drugs and Organics Ltd?

The Market Cap of Mangalam Drugs and Organics Ltd is 170 Cr..

What is the current Stock Price of Mangalam Drugs and Organics Ltd as on 30 May 2024?

The current stock price of Mangalam Drugs and Organics Ltd as on 30 May 2024 is ₹107.

What is the High / Low of Mangalam Drugs and Organics Ltd stocks in FY 2024?

In FY 2024, the High / Low of Mangalam Drugs and Organics Ltd stocks is 132/85.2.

What is the Stock P/E of Mangalam Drugs and Organics Ltd?

The Stock P/E of Mangalam Drugs and Organics Ltd is .

What is the Book Value of Mangalam Drugs and Organics Ltd?

The Book Value of Mangalam Drugs and Organics Ltd is 89.9.

What is the Dividend Yield of Mangalam Drugs and Organics Ltd?

The Dividend Yield of Mangalam Drugs and Organics Ltd is 0.00 %.

What is the ROCE of Mangalam Drugs and Organics Ltd?

The ROCE of Mangalam Drugs and Organics Ltd is 1.19 %.

What is the ROE of Mangalam Drugs and Organics Ltd?

The ROE of Mangalam Drugs and Organics Ltd is 6.15 %.

What is the Face Value of Mangalam Drugs and Organics Ltd?

The Face Value of Mangalam Drugs and Organics Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Mangalam Drugs and Organics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE